Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792075 | 1.00 | KMT2A (0.90) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL29370234 | 1.00 | KMT2A (0.90) | KMT2AHTTEPHX2CASP3FABP7 | |
| Water SCHEMBL21809392 | 0.99 | KMT2A (0.88) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL97174 | 0.96 | KMT2A (0.97) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL29482640 | 0.96 | KMT2A (0.97) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL2182769 | 0.95 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178760 | 0.95 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178762 | 0.95 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178759 | 0.95 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178758 | 0.95 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703736-A | Multi-target inhibitors targeting HDAC and NAD synthesis and uses thereof | 中国海洋大学 | 2023-02-17 | — | — | CN | claimed |
| EP-1506970-A1 | COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME | Diverdrugs, S.L. (ES) | 2005-02-16 | — | — | EP | claimed |
| US-6140493-A | BIFUNCTIONAL SOLID SUPPORT HAVING A PLURALITY OF AMINE ACTIVE SITES AND A PLURALITY OF HYDROXYL ACTIVE SITES; FOR SOLID PHASE SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 2000-10-31 | — | — | US | claimed |
| EP-0604552-A1 | METHOD OF SYNTHESIZING DIVERSE COLLECTIONS OF OLIGOMERS. | AFFYMAX TECH NV (AN) | 1994-07-06 | — | — | EP | claimed |
| EP-0604552-A4 | METHOD OF SYNTHESIZING DIVERSE COLLECTIONS OF OLIGOMERS. | AFFYMAX TECH NV (AN) | 1993-08-02 | — | — | EP | claimed |
| WO-1993006121-A1 | METHOD OF SYNTHESIZING DIVERSE COLLECTIONS OF OLIGOMERS | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-04-01 | — | — | WO | claimed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| WO-2025224092-A1 | PEPTIDE-BASED RADIOPHARMACEUTICALS FOR NON-INVASIVE IMAGING OF THE FUNCTIONAL LIVER RESERVE | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640240-A1 | PEPTIDE-BASED RADIOPHARMACEUTICALS FOR NON-INVASIVE IMAGING OF THE FUNCTIONAL LIVER RESERVE | Medizinische Universität Innsbruck (AT) | 2025-10-29 | — | — | EP | disclosed |
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | disclosed |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2025-07-31 | — | — | US | disclosed |
| WO-1993006121-A1 | METHOD OF SYNTHESIZING DIVERSE COLLECTIONS OF OLIGOMERS | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-04-01 | — | — | WO | disclosed |
| WO-1992002641-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002532-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0339695-A2 | A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 1989-11-02 | — | — | EP | disclosed |
| EP-0313219-A2 | Non-nucleotide linking reagents for nucleotide probes | GEN-PROBE INCORPORATED (US) | 1989-04-26 | — | — | EP | disclosed |
| WO-1989002439-A1 | NON-NUCLEOTIDE LINKING REAGENTS FOR NUCLEOTIDE PROBES | ML TECHNOLOGY VENTURES, L.P. (US) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | MTREX, DCLRE1B, ADAR | KMT2A 2608/4885HTT 1995/4885EPHX2 2274/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885HTT 4056/4885EPHX2 4299/4885 |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | DNTT, NCL, NT5C3B | KMT2A 4217/4885HTT 2257/4885EPHX2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.